California, USA (CU)_ At the Benzinga Global Small Cap Business Conference, Dr. John Kovach, the CEO and founder of Lixte Biotechnology Holdings, Inc., expressed optimism about his company’s first-in-class protein phosphatase inhibitor, LB-100, as a novel complement to cancer treatment. In numerous animal models, Lixte Biotechnology (NASDAQ: LIXT) has developed and patented a range of innovative medications that improve the effectiveness of current anti-cancer therapy. Lixte’s LB-100 has been proved to improve the anti-tumor activity of traditional chemotherapy, radiation, and immunotherapy without increasing toxicity in more than 40 preclinical investigations.
Dr. Kovach highlighted that Lixte’s substantial international patent portfolio will cover patents for…
